Clinical Trials
3,160 trialsSTARTRK-2
Hoffmann-La Roche
ESME OC
UNICANCER
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
Aalborg University Hospital
NAPISTAR1-01
Tubulis GmbH
RAINFOL-02
Genmab
FRAmework-01
Eli Lilly and Company
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Boehringer Ingelheim
ADAPT-OC
Queen's University
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
GLORIOSA
AbbVie
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
RAINFOL-01
Genmab
EVEREST-2
A2 Biotherapeutics Inc.
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
RSPH5973-23
Emory University
DO-01
Daiichi Sankyo
MAESTRA 1
Incyte Corporation
MAESTRA 2
Incyte Corporation
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Stemline Therapeutics, Inc.
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
University of Washington
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies
National Institutes of Health Clinical Center (CC)
PIPACOVA
Hospices Civils de Lyon
SCOUT-1
AstraZeneca
VERDI
Dana-Farber Cancer Institute
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
M.D. Anderson Cancer Center
PIKALO-1
Eli Lilly and Company
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
EXCEED
Eli Lilly and Company
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Jacobio Pharmaceuticals Co., Ltd.
NEXUS-01
Eli Lilly and Company
BIOC
KU Leuven
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
FiREBOLT
Eli Lilly and Company
TroFuse-021
Merck Sharp & Dohme LLC
RAINFOL-02
Genmab
PROMPT
University College, London
A Study of Intra-operative Imaging in Women With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Oncoinvent Solutions AS
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
DESCENT-1
A2 Biotherapeutics Inc.
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
AstraZeneca
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NRG Oncology
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center